KTTA
HEALTHCAREPasithea Therapeutics Corp
$0.85-0.00 (-0.01%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving KTTA Today?
No stock-specific AI insight has been generated for KTTA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.28$2.06
$0.85
Fundamentals
Market Cap$21M
P/E Ratio—
EPS$-2.91
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume232K
Avg Volume (10D)—
Shares Outstanding24.9M
KTTA News
20 articles- Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical OfficerYahoo Finance·May 4, 2026
- Is Pasithea Therapeutics (NASDAQ:KTTA) In A Good Position To Deliver On Growth Plans?Yahoo Finance·May 3, 2026
- Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)Yahoo Finance·Apr 20, 2026
- Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant MorbidityYahoo Finance·Apr 1, 2026
- Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceYahoo Finance·Feb 17, 2026
- Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release TimelinesYahoo Finance·Jan 13, 2026
- Insiders Buying Pasithea Therapeutics Might Wish They Invested More, Stock Gains 10%Yahoo Finance·Dec 4, 2025
- Lawrence Steinman Bought 201% More Shares In Pasithea TherapeuticsYahoo Finance·Dec 4, 2025
- Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common StockYahoo Finance·Dec 2, 2025
- Weekly Roundup on the Cannabis Sector & Psychedelic SectorYahoo Finance·Dec 1, 2025
- US Equity Markets Close Higher During Thanksgiving Week as Interest Rate Cut Expectations Remain StrongYahoo Finance·Nov 28, 2025
- BC-Most Active StocksYahoo Finance·Nov 28, 2025
- Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common StockYahoo Finance·Nov 28, 2025
- Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALSYahoo Finance·Nov 25, 2025
- Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) DataYahoo Finance·Nov 24, 2025
- Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 PatientsYahoo Finance·Nov 21, 2025
- Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer StudyYahoo Finance·Nov 20, 2025
- Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 PatientsYahoo Finance·Nov 4, 2025
- Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 PatientsYahoo Finance·Sep 16, 2025
- Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 PatientsYahoo Finance·Sep 8, 2025
All 20 articles loaded
Price Data
Open$0.83
Previous Close$0.85
Day High$0.89
Day Low$0.83
52 Week High$2.06
52 Week Low$0.28
52-Week Range
$0.28$2.06
$0.85
Fundamentals
Market Cap$21M
P/E Ratio—
EPS$-2.91
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume232K
Avg Volume (10D)—
Shares Outstanding24.9M
About Pasithea Therapeutics Corp
Pasithea Therapeutics Corp. The company is headquartered in Miami Beach, Florida.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—